Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.90 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)874.79K
Market Cap
$194.69M
Enterprise Value$234.16M
Total Cash (Recent Filing)$59.78M
Total Debt (Recent Filing)$59.50M
Price to Earnings (P/E)―
Beta2.65
Next Earnings
Jul 31, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding82,844,850
10 Day Avg. Volume625,289
30 Day Avg. Volume874,790
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.10
Price to Sales (P/S)0.00
P/FCF Ratio102.29
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$5.88Price Target Upside156.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Codexis News
PremiumCompany Announcements
Codexis Stockholders Approve Key Proposals at Annual Meeting
PremiumCompany Announcements
Codexis Earnings Call: Strategic Growth Amid ChallengesPremiumCompany Announcements
Codexis Reports Q1 2025 Financial Results and Strategic Progress
Bulls Say, Bears Say
Bulls Say
ContractsThe company secured the first revenue-generating contract for the ECO Synthesis Innovation Lab and met industrial grade criteria across first-generation enzymes.
Customer OrdersCDXS delivered the first order to a large pharma customer and secured an initial order from a second customer, which is a drug innovator.
Financial OutlookCodexis has cash to fund operations to cash flow positivity by the end of 2026.
Bears Say
EarningsQ4 revenues of $21.5M missed consensus estimates of $27.4M.
Revenue PerformanceRevenues of $7.5M were 56% lower year-over-year, missing expectations by $2.2M.
Ownership Overview
17.67% Insiders
19.84% Mutual Funds
38.26% Other Institutional Investors
14.00% Public Companies and Individual Investors
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $1.90 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $194.69M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Jul 31, 2025 which is in 39 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on May 14, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.237 by -$0.013.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.19.
How many shares outstanding does Codexis have?
Codexis has 82,844,850 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.237. Following the earnings report the stock price went up 1.619%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
Codexis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (156.77% Upside)
$5.88 (156.77% Upside)
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.50%
12-Months-Change
Fundamentals
Return on Equity
-115.53%
Trailing 12-Months
Asset Growth
-13.82%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Company Deck
CDXS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite challenges such as a significant year-over-year revenue decline and increased net loss, Codexis maintains a strong financial position and projects future growth driven by advancements in its ecosynthesis platform and machine learning capabilities. The sentiment remains cautiously positive due to strategic progress in key areas.Read More>CDXS Stock 12 Month Forecast
Average Price Target
$5.88
▲(156.77%Upside)
Technical Analysis
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Atea Pharmaceuticals
―
Terns Pharmaceuticals
―
Nuvectis Pharma
―